Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Barclays

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) was downgraded by stock analysts at Barclays from a "strong-buy" rating to a "hold" rating in a note issued to investors on Tuesday,Zacks.com reports.

SRPT has been the topic of several other research reports. Baird R W cut Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. Oppenheimer reduced their target price on Sarepta Therapeutics from $45.00 to $41.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. BMO Capital Markets reiterated a "market perform" rating and issued a $50.00 target price (down previously from $70.00) on shares of Sarepta Therapeutics in a report on Monday. Bank of America reduced their target price on Sarepta Therapeutics from $28.00 to $20.00 and set a "neutral" rating on the stock in a report on Friday, July 18th. Finally, William Blair reiterated a "market perform" rating on shares of Sarepta Therapeutics in a report on Thursday, July 17th. Two research analysts have rated the stock with a sell rating, nineteen have given a hold rating and eight have given a buy rating to the company. According to MarketBeat, Sarepta Therapeutics presently has an average rating of "Hold" and a consensus target price of $52.92.

Sarepta Therapeutics Stock Up 2.2%

SRPT opened at $13.61 on Tuesday. The business has a 50 day moving average price of $28.42 and a two-hundred day moving average price of $67.58. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The company has a market cap of $1.34 billion, a PE ratio of -5.06 and a beta of 0.45. Sarepta Therapeutics has a 52 week low of $12.24 and a 52 week high of $150.48.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same period last year, the company posted $0.73 earnings per share. The business's quarterly revenue was up 80.2% on a year-over-year basis. As a group, research analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC increased its stake in shares of Sarepta Therapeutics by 22.1% in the fourth quarter. Commonwealth Equity Services LLC now owns 6,357 shares of the biotechnology company's stock worth $773,000 after acquiring an additional 1,151 shares during the last quarter. Corient Private Wealth LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter worth $786,000. Teacher Retirement System of Texas increased its stake in shares of Sarepta Therapeutics by 19.1% in the fourth quarter. Teacher Retirement System of Texas now owns 25,412 shares of the biotechnology company's stock worth $3,090,000 after acquiring an additional 4,076 shares during the last quarter. Sei Investments Co. increased its stake in shares of Sarepta Therapeutics by 31.7% in the fourth quarter. Sei Investments Co. now owns 23,935 shares of the biotechnology company's stock worth $2,910,000 after acquiring an additional 5,764 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Sarepta Therapeutics in the fourth quarter worth $2,164,000. Institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.